SOURCE: InoLife Technologies Inc.

September 08, 2010 14:00 ET

InoLife Technologies, Inc. Announces Immediate Availability of the Cytochrome P450 2C1 Plavix Metabolizing Test to the Medical Industry

RALEIGH, NC--(Marketwire - September 8, 2010) -  InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company, is extremely pleased that their recently presented Cytochrome P450 2C1 test to determine a person's ability to metabolize Plavix is immediately available to the medical industry which includes physicians, hospitals, medical clinics, and pharmacies. Physicians are currently placing orders on a daily basis and are incorporating the Cytochrome P450 2C1 Plavix Metabolizing test into their patients health programs. 

InoLife's Cytochrome P450 2C1 test is currently being used to identify how a patient's genetics may affect the body's response to Plavix (Clopidogrel). The test is available through the medical community only including physicians, hospitals, and medical clinics. This test is not available for sale to the general public.

According to the FDA in a press release dated March 12th, 2010 it is estimated that 2 percent to 14 percent of the U.S. population are poor metabolizers of certain medications. In 2009 the Federal Drug Administration approved wording on the drug label encouraging genetic testing for DNA variants based on specific risks. It is important to note that this drug metabolism test is not all-inclusive and is for the physician's guidance only.

InoLife has incorporated the EasiCollect™ System, which combines an optimized foam collection surface with an FTA card for collection of buccal cells and preservation of DNA. InoLife prides itself in providing the EasiCollect™ System that adheres to the strict guidelines of the Clinical Laboratory Improvement Amendments (CLIA) that monitors approximately 200,000 laboratory entities. The Center for Medicare & Medicaid Services regulates all laboratory testing (except research) performed on humans in the U.S. through CLIA.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company's mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife's products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

(Plavix is a trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.)

Forward-Looking Statements
Safe Harbor Statement under the Private securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

Contact Information